Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. [electronic resource]
Producer: 20080826Description: 698-707 p. digitalISSN:- 1097-4652
- Animals
- Antibodies, Monoclonal -- pharmacology
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Boronic Acids -- pharmacology
- Bortezomib
- Cell Line, Tumor -- drug effects
- Cetuximab
- Dose-Response Relationship, Drug
- Drug Combinations
- Drug Synergism
- Enzyme Activation
- ErbB Receptors -- antagonists & inhibitors
- Gefitinib
- Humans
- Mitogen-Activated Protein Kinases -- genetics
- Piperidines -- pharmacology
- Proteasome Endopeptidase Complex -- metabolism
- Proteasome Inhibitors
- Proto-Oncogene Proteins c-akt -- genetics
- Pyrazines -- pharmacology
- Quinazolines -- pharmacology
- Signal Transduction -- physiology
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.